Trials / Completed
CompletedNCT00906438
Effects of 2006-RD-05 on Salivary and Serum Immunoglobulin A (IgA) Levels in Healthy Subjects
Effects of 2006-RD-05 on Salivary and Serum IgA Levels in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- innoVactiv Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
It is already known from animal studies that the study drug can improve mucosal immunity as shown by increased serum and mucosal IgA secretion. This study will evaluate the safety of an oral intake of the natural product 2006-RD-05 at the recommended daily dose of 300 mg. In addition, this trial will aim to determine if this intake is able ot improve serum and salivary IgA synthesis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | 2006-RD-05 | 300 mg daily, once a day for 28 consecutive days |
| DIETARY_SUPPLEMENT | Placebo | Capsule similar in shape, weight and color from active, once a day for 28 consecutive days |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2009-08-01
- Completion
- 2009-10-01
- First posted
- 2009-05-21
- Last updated
- 2009-10-29
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00906438. Inclusion in this directory is not an endorsement.